Characteristics of LACE cohort by hours/week of moderate intensity physical activity
| Hours per week of moderate activity | P* | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <1 h (n = 490) | 1-<3 h (n = 502) | 3-<6 h (n = 523) | ≥6 h (n = 433) | |||||||
| Age at enrollment, mean y (SD) | 62.8 (11.1) | 60.0 (11.2) | 59.9 (10.3) | 59.6 (10.2) | <0.0001 | |||||
| Race, n (%) | 0.15 | |||||||||
| White | 383 (78.2) | 409 (81.5) | 432 (82.6) | 362 (83.6) | ||||||
| Other | 107 (21.8) | 93 (18.5) | 91 (17.4) | 71 (16.4) | ||||||
| Education, n (%) | 0.0001 | |||||||||
| High school graduate or less | 167 (34.1) | 125 (24.9) | 116 (22.2) | 116 (26.9) | ||||||
| Some college | 178 (36.3) | 201 (40.0) | 198 (37.9) | 143 (33.2) | ||||||
| College graduate or more | 145 (29.6) | 176 (35.1) | 209 (40.0) | 172 (39.9) | ||||||
| Smoking status, n (%) | 0.40 | |||||||||
| Never | 263 (53.8) | 279 (55.8) | 269 (51.6) | 234 (54.3) | ||||||
| Past | 184 (37.6) | 187 (37.4) | 222 (42.6) | 165 (38.3) | ||||||
| Current | 42 (8.6) | 34 (6.8) | 30 (5.8) | 32 (7.4) | ||||||
| BMI at enrollment, mean kg/m2 (SD) | 28.9 (6.3) | 27.9 (5.8) | 26.9 (5.6) | 26.2 (5.1) | <0.0001 | |||||
| Weight at 18 y, mean lbs (SD) | 120.5 (17.6) | 120.4 (16.2) | 122.5 (17.3) | 120.6 (16.9) | 0.16 | |||||
| Menopausal status, n (%) | 0.03 | |||||||||
| Postmenopausal | 340 (69.4) | 315 (62.8) | 333 (63.5) | 286 (65.9) | ||||||
| Premenopausal | 95 (19.4) | 117 (23.3) | 100 (19.1) | 97 (22.4) | ||||||
| Undetermined | 55 (11.2) | 70 (13.9) | 91 (17.4) | 51 (11.7) | ||||||
| Family history of breast cancer, n (%) | 0.74 | |||||||||
| No | 389 (79.4) | 408 (81.3) | 411 (78.6) | 343 (79.2) | ||||||
| Yes | 101 (20.6) | 94 (18.7) | 112 (21.4) | 90 (20.8) | ||||||
| Stage, n (%) | 0.21 | |||||||||
| I | 218 (44.7) | 233 (46.5) | 257 (49.1) | 219 (50.6) | ||||||
| IIa | 163 (33.4) | 180 (35.9) | 160 (30.5) | 147 (34.0) | ||||||
| IIb | 94 (19.3) | 72 (14.4) | 90 (17.2) | 56 (12.9) | ||||||
| IIIa | 13 (2.7) | 16 (3.2) | 17 (3.2) | 11 (2.5) | ||||||
| Type of surgery, n (%) | 0.60 | |||||||||
| Conserving | 244 (49.8) | 265 (52.8) | 255 (48.7) | 218 (50.3) | ||||||
| Mastectomy | 246 (50.2) | 237 (47.2) | 269 (51.3) | 215 (49.7) | ||||||
| Chemotherapy, n (%) | 0.03 | |||||||||
| No | 232 (48.2) | 195 (39.0) | 230 (44.3) | 188 (43.5) | ||||||
| Yes | 249 (51.8) | 305 (61.0) | 289 (55.7) | 244 (56.5) | ||||||
| Radiation therapy, n (%) | 0.83 | |||||||||
| No | 179 (38.2) | 176 (35.6) | 197 (37.9) | 155 (36.8) | ||||||
| Yes | 290 (61.8) | 319 (64.4) | 323 (62.1) | 266 (63.2) | ||||||
| Number of positive nodes, n (%) | 0.06 | |||||||||
| Node negative | 282 (60.6) | 291 (62.1) | 319 (65.8) | 283 (68.9) | ||||||
| 1-3 | 125 (26.9) | 121 (25.8) | 121 (24.9) | 99 (24.1) | ||||||
| ≥3 | 58 (12.5) | 57 (12.1) | 45 (9.3) | 29 (7.1) | ||||||
| Tamoxifen use, n (%) | .69 | |||||||||
| No | 116 (23.7) | 121 (24.1) | 113 (21.6) | 94 (21.7) | ||||||
| Yes | 374 (76.3) | 381 (75.9) | 411 (78.4) | 340 (78.3) | ||||||
| ER/PR receptor status, n (%) | 0.33 | |||||||||
| ER+, PR+ | 330 (68.6) | 319 (64.4) | 366 (70.8) | 296 (69.0) | ||||||
| ER+, PR- | 62 (12.9) | 73 (14.8) | 71 (13.7) | 67 (15.6) | ||||||
| ER-, PR+ | 6 (1.2) | 12 (2.4) | 9 (1.7) | 7 (1.6) | ||||||
| ER-, PR- | 83 (17.3) | 91 (18.4) | 71 (13.7) | 59 (13.8) | ||||||
| Time from diagnosis to enrollment, mean y (SD) | 1.9 (0.5) | 1.9 (0.6) | 1.9 (0.6) | 1.9 (0.6) | 0.91 | |||||
| Follow-up time, mean y (SD) | ||||||||||
| To recurrence | 7.0 (1.6) | 7.2 (1.6) | 7.2 (1.5) | 7.2 (1.5) | 0.08 | |||||
| To death | 7.2 (1.3) | 7.4 (1.3) | 7.4 (1.2) | 7.4 (1.3) | 0.08 | |||||
↵* ANOVA to test for differences in means of continuous variables; chi-square tests to evaluate differences in proportions for categorical variables.